Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
311. |
ECCT/24/07/02 | TMC278LAHTX4002 A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Longacting Combination Therapy Studies |
Principal Investigator(s) 1. Reena Shah Site(s) in Kenya 1. Aga Khan University Hospital Nairobi (Nairobi City county) 2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county) 3. Kenya Medical Research Institute-Walter Reed Program (KEMRI-WRP) Clinical Research Site, Kericho, Kenya (Kericho county) 4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county) 5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Nairobi City county) |
View |
312. |
ECCT/23/10/02 | MATRIX-001 protocol A Phase I Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety, Pharmacokinetics, and Modeled Pharmacodynamics of a Vaginal Insert Containing Tenofovir Alafenamide and Elvitegravir |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya KEMRI-CCR PHRD Thika |
View |
313. |
ECCT/13/07/01 | HIVCORE004/N004 A phase I/IIa clinical trial of universal HIV-1 vaccines pSG2.HIVconsv DNA, MVA.HIVconsv and ChAdV63.HIVconsv in combined regimens in healthy HIV-1/2-negative adults in Nairobi. |
Principal Investigator(s) 1. Prof. Walter Godfrey Jaoko Site(s) in Kenya KAVI-KANGEMI RESEARCH SITE |
View |
314. |
ECCT/20/05/01 | ChAdOx1 nCoV-19 trial A phase Ib/II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya |
Principal Investigator(s) 1. George Warimwe Site(s) in Kenya KEMRI-CGMRC |
View |
315. |
ECCT/10/05/02 | AERAS-402 A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter, Proof-of-concept Study to Evaluate the Safety and Efficacy of AERAS-402 in BCG-vaccinated, HIV-uninfected Infants Without Evidence of Tuberculosis |
Principal Investigator(s) 1. Dr Videlis Nduba 2. Dr Grace Kiringa Kaguthi Site(s) in Kenya KEMRI-CDC |
View |